menu search

FMS / Fresenius Medical (FMS) Q3 Earnings Miss, Operating Margin Up

Fresenius Medical (FMS) Q3 Earnings Miss, Operating Margin Up
Fresenius Medical's (FMS) third-quarter revenues suffer due to unfavorable currency movement. However, the company's transformational plans continue to benefit its operating income. Read More
Posted: Nov 3 2023, 11:18
Author Name: Zacks Investment Research
Views: 030114

FMS News  

Fresenius Medical (FMS) Q3 Earnings Miss, Operating Margin Up

By Zacks Investment Research
November 3, 2023

Fresenius Medical (FMS) Q3 Earnings Miss, Operating Margin Up

Fresenius Medical's (FMS) third-quarter revenues suffer due to unfavorable currency movement. However, the company's transformational plans continue t more_horizontal

Fresenius Medical Care AG & Co. KGaA (FMS) Q3 2023 Earnings Call Transcript

By Seeking Alpha
November 2, 2023

Fresenius Medical Care AG & Co. KGaA (FMS) Q3 2023 Earnings Call Transcript

Fresenius Medical Care AG & Co. KGaA (FMS) Q3 2023 Earnings Call Transcript more_horizontal

Top Medical Stocks to Buy Amid Recent Market Volatility

By Zacks Investment Research
October 23, 2023

Top Medical Stocks to Buy Amid Recent Market Volatility

Several Zacks Medical sector stocks were recently added to the Zacks Rank #1 (Strong Buy) list over the last week and should be viable options for inv more_horizontal

Here's Why You Should Retain Fresenius Medical (FMS) for Now

By Zacks Investment Research
October 16, 2023

Here's Why You Should Retain Fresenius Medical (FMS) for Now

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe. more_horizontal

Fresenius Medical: use of drugs like Ozempic has neutral effect on dialysis patient numbers

By Reuters
October 12, 2023

Fresenius Medical: use of drugs like Ozempic has neutral effect on dialysis patient numbers

Germany's Fresenius Medical Care , said that use of Ozempic, and other diabetes and weight-loss drugs of the same class, would have an overall neutral more_horizontal

Why Shares of Fresenius Medical Care Were Dropping on Wednesday

By The Motley Fool
October 11, 2023

Why Shares of Fresenius Medical Care Were Dropping on Wednesday

Novo Nordisk ended a phase 3 trial early for Ozempic for preventing kidney disease because the trial was so successful. Fresenius and other dialysis-c more_horizontal

Dialysis company shares plunge after Ozempic trial success vs. kidney trouble

By Market Watch
October 11, 2023

Dialysis company shares plunge after Ozempic trial success vs. kidney trouble

The trial success of Novo Nordisk's hit drug against kidney failure sent shares of a German kidney dialysis services firm plummeting on Wednesday. more_horizontal

Here's Why You Should Retain Fresenius Medical (FMS) for Now

By Zacks Investment Research
September 15, 2023

Here's Why You Should Retain Fresenius Medical (FMS) for Now

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe. more_horizontal


Search within

Pages Search Results: